NASDAQ:VERU - Nasdaq - US92536C1036 - Common Stock - Currency: USD
We assign a fundamental rating of 3 out of 10 to VERU. VERU was compared to 194 industry peers in the Pharmaceuticals industry. The financial health of VERU is average, but there are quite some concerns on its profitability. VERU is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -96.59% | ||
ROE | -144.48% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 39.7% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -9.24 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 4.47 | ||
Quick Ratio | 4.47 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
0.5608
-0.04 (-6.53%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 5.57 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 3.09 | ||
P/tB | 4.16 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -96.59% | ||
ROE | -144.48% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 39.7% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 61.05% | ||
Cap/Sales | 1.08% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 4.47 | ||
Quick Ratio | 4.47 | ||
Altman-Z | -9.24 |